ReviewCancers2026
From Bulk to Spatially Resolved Single-Cell Omics: Shaping Future Prognostic and Predictive Stratification in Head and Neck Squamous Cell Carcinoma.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) is characterized by marked intratumoral heterogeneity and complex tumor-immune-stromal interactions, which shape therapeutic response and clinical outcome. Despite extensive transcriptomic efforts, bulk RNA sequencing has faced significant limitations, often failing to generate robust prognostic or predictive biomarkers, highlighting the need for approaches capable of resolving the cellular and spatial complexity of the tumor ecosystem. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) have refined our understanding of HNSCC biology by enabling high-resolution mapping of malignant, stem-like, immune, and stromal compartments. Three major spatial domains have been defined in HNSCC: tumor core (TC), tumor invasion front (TIF), and leading edge (LE). Each ecosystem exhibits distinct cellular programs that promote immune evasion, tumor dissemination, and therapy resistance, particularly in high-risk clinical settings. In this Review, we integrate recent single-cell and spatial studies and propose a translational framework linking ecosystem architecture with clinical stratification across resectable locally advanced (r-LAD), unresectable locally advanced (u-LAD), and recurrent/metastatic (R/M) disease. We further discuss how spatially resolved transcriptomic approaches may support biomarker discovery and hypothesis generation for risk stratification and trial design, while emphasizing that clinical implementation remains limited by cohort size, methodological heterogeneity, and the need for large-scale prospective validation. Finally, we outline key methodological and translational challenges that must be addressed before these technologies can reliably inform precision oncology and decision-making in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.